(Q38084132)

28 August 2017

title

Newer developments in the immunotherapy of malignant melanoma (English)

1 reference

28 August 2017

1 reference

3

Thomas E Ichim

1 reference

28 August 2017

Benjamin Maslin

1

1 reference

28 August 2017

Doru T Alexandrescu

series ordinal

2

1 reference

28 August 2017

Constantin A Dasanu

series ordinal

4

1 reference

28 August 2017

publication date

22 February 2013

1 reference

Journal of Oncology Pharmacy Practice

28 August 2017

published in

1 reference

28 August 2017

volume

20

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

3-10

1 reference

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Exosomes bearing HLA-G are released by melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Tumor-released microvesicles as vehicles of immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Tumor exosomes inhibit differentiation of bone marrow dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Immunity against cancer: lessons learned from melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Immune modulation by melanoma-derived factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Analyses and perspectives in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

A review of recent findings involving interleukin-2-based cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Different effects of interferon-alpha on melanoma cell lines: a study on telomerase reverse transcriptase, telomerase activity and apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Increased survival from stage IV melanoma associated with fewer regulatory T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Toll-like receptors: linking innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

CD40 and dendritic cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Tumor Immunotherapy Directed at PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155212472702

21 January 2018

Identifiers

DOI

10.1177/1078155212472702

1 reference

28 August 2017

1 reference